Japan approvals include Hemlibra, Shingrix Galafold

Japan approved a basket of drugs including hemophilia drug Hemlibra emicizumab from Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), shingles vaccine Shingrix from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Fabry's disease drug Galafold migalastat from Amicus Therapeutics Inc. (NASDAQ:FOLD).

Japan's Ministry of Health, Labour and Welfare (MHLW) approved Hemlibra to prevent or reduce the frequency of bleeding episodes in patients with hemophilia

Read the full 587 word article

How to gain access

Continue reading with a
two-week free trial.